Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Melissa Kerr

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
Early Intervention in Psychiatry|November 7, 2015
Youth Depression Alleviation-Augmentation with an anti-inflammatory agent (YoDA-A): protocol and rationale for a placebo-controlled randomized trial of rosuvastatin and aspirinAmelia L Quinn, Olivia M Dean, Christopher G Davey, et al.
JAMA Psychiatry|June 28, 2023
A Sequential Adaptive Intervention Strategy Targeting Remission and Functional Recovery in Young People at Ultrahigh Risk of Psychosis: The Staged Treatment in Early Psychosis (STEP) Sequential Multiple Assignment Randomized TrialPatrick D McGorry, Cristina Mei, G Paul Amminger, et al.
Schizophrenia Bulletin|September 6, 2024
Psychosis Risk: Time to Look Empirically at a First-step Economical-pragmatic Way to Examine Anomalous Self-experience. Exploring the SQuEASE-11Paul Møller, Barnaby Nelson, Patrick D McGorry, et al.
BMC Medicine|January 18, 2020
Youth Depression Alleviation with Anti-inflammatory Agents (YoDA-A): a randomised clinical trial of rosuvastatin and aspirinMichael Berk, Mohammadreza Mohebbi, Olivia M Dean, et al.
Schizophrenia Bulletin|December 20, 2024
Characterizing the Clinical Trajectory and Predicting Persistence and Deterioration of Attenuated Psychotic Symptoms in Ultra-High-Risk IndividualsCassandra Wannan, Isabelle Scott, Dominic Dwyer, et al.
Early Intervention in Psychiatry|July 1, 2026
Exploring the Relationship Between Inflammatory Biomarkers and Negative Symptoms Subtypes in Individuals at Ultra-High Risk for PsychosisDulari Hakamuwa Lekamlage, Ling Min Amelia Ang, Luba Sominsky, et al.
Schizophrenia Bulletin|March 7, 2024
Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for PsychosisCassandra M J Wannan, Barnaby Nelson, Jean Addington, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Early Intervention in Psychiatry|November 7, 2015
Youth Depression Alleviation-Augmentation with an anti-inflammatory agent (YoDA-A): protocol and rationale for a placebo-controlled randomized trial of rosuvastatin and aspirinAmelia L Quinn, Olivia M Dean, Christopher G Davey, et al.
JAMA Psychiatry|June 28, 2023
A Sequential Adaptive Intervention Strategy Targeting Remission and Functional Recovery in Young People at Ultrahigh Risk of Psychosis: The Staged Treatment in Early Psychosis (STEP) Sequential Multiple Assignment Randomized TrialPatrick D McGorry, Cristina Mei, G Paul Amminger, et al.
Schizophrenia Bulletin|September 6, 2024
Psychosis Risk: Time to Look Empirically at a First-step Economical-pragmatic Way to Examine Anomalous Self-experience. Exploring the SQuEASE-11Paul Møller, Barnaby Nelson, Patrick D McGorry, et al.
BMC Medicine|January 18, 2020
Youth Depression Alleviation with Anti-inflammatory Agents (YoDA-A): a randomised clinical trial of rosuvastatin and aspirinMichael Berk, Mohammadreza Mohebbi, Olivia M Dean, et al.
Schizophrenia Bulletin|December 20, 2024
Characterizing the Clinical Trajectory and Predicting Persistence and Deterioration of Attenuated Psychotic Symptoms in Ultra-High-Risk IndividualsCassandra Wannan, Isabelle Scott, Dominic Dwyer, et al.
Early Intervention in Psychiatry|July 1, 2026
Exploring the Relationship Between Inflammatory Biomarkers and Negative Symptoms Subtypes in Individuals at Ultra-High Risk for PsychosisDulari Hakamuwa Lekamlage, Ling Min Amelia Ang, Luba Sominsky, et al.
Schizophrenia Bulletin|March 7, 2024
Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for PsychosisCassandra M J Wannan, Barnaby Nelson, Jean Addington, et al.
Pageof 3